Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Comment by Lykitison Jul 07, 2014 11:47am
191 Views
Post# 22721305

RE:RE:RE:RE:264RAD

RE:RE:RE:RE:264RADoh man.

Is the tehnology going to be tested in mice for years before human trials commence? I see no timeline for human trials anywhere now.

Those are NOT things I, personally, want to read in any future news release.
Want I want to read is that x, y and z company, in quick successive press releases, feeling confident in MedImmune's "trail-blazing" footsteps, are lining up to pay $x for trial licenses to test with their own products.
And the next press release after that would reflect (AZ)MedImmune's growing sentiment that they have to "move" to fend off would-be suitors, and maintain exclusivity.... a.k.a. a buyout offer.
And the next press release after that, before buyout expiry, would reflect Pfizer's "take that!" sentiment, with a much higher buyout offer.
And then EVERYONE is looking at a hyped up BTI and considering the sheer magnitude of what's at stake.
So... mice trials? Human trials? Not interested.
Bring me the juicy headlines that reflect what this game-changing company has got to offer and that everyone now realizes they MUST have.
"Dream-big" Lykitis.
Bullboard Posts